Ayako Shiono
YOU?
Author Swipe
View article: Supplementary materials from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Supplementary materials from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy Open
Legends of Supplementary Figures and Tables, and Supplementary Methods.
View article: Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy Open
Supplementary Table 2, 4, 5, 6, 7.
View article: Figure S1,S2,S3,S4,S5,S6,S7,S8,S9 and S10 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Figure S1,S2,S3,S4,S5,S6,S7,S8,S9 and S10 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy Open
Supplementary Figures 1-10.
View article: A Case of Combined Small-cell Carcinoma and Adenocarcinoma of the Lung With <i>EGFR</i> Exon 19 Deletion Identified <i>via</i> Liquid Genomic Profiling
A Case of Combined Small-cell Carcinoma and Adenocarcinoma of the Lung With <i>EGFR</i> Exon 19 Deletion Identified <i>via</i> Liquid Genomic Profiling Open
This case illustrates the clinical value of liquid biopsy in detecting actionable mutations in patients with mixed histological lung cancers where tissue-based testing is inconclusive. Liquid biopsy enabled a personalized therapeutic appro…
View article: Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy
Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy Open
Trophoblast surface antigen 2 (TROP2) is strongly expressed in patients with non-small cell lung cancer (NSCLC), and its overexpression is closely associated with a worse prognosis. Recently, a novel TROP2-directed antibody-drug conjugate …
View article: Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort study
Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort study Open
NLR was identified as a significant biomarker for predicting AMR outcomes after prior CTI in patients with ES-SCLC.
View article: Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations Open
View article: Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study
Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study Open
Main Problem The efficacy and safety of platinum‐based chemotherapy with programmed death‐1 (PD‐1) blockade after chemoradiotherapy (CRT) for the treatment of limited disease (LD) small cell lung cancer (SCLC) is unknown. This study aimed …
View article: Th7R Cells: CD4⁺ T-Cell Partners That Drive Tpex-Mediated Antitumor Immunity in the Tumor Microenvironment
Th7R Cells: CD4⁺ T-Cell Partners That Drive Tpex-Mediated Antitumor Immunity in the Tumor Microenvironment Open
The priming, expansion, and function of CD8⁺ T cells depend on CD4⁺ T-cell help via dendritic cells. Precursor exhausted T cells (Tpex) maintain self-renewal and supply cytotoxic CD8⁺ T cells in the tumor microenvironment (TME), but their …
View article: Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study
Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study Open
Background and Objectives: The comparative efficacy and safety of nivolumab plus ipilimumab (Nivo-Ipi) combination therapy between patients with either postoperative recurrent non-small cell lung cancer (NSCLC) or inoperable stage III/IV N…
View article: Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy
Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy Open
Liver metastasis is a significant predictor of outcomes after chemoimmunotherapy in patients with ES-SCLC. The maximal diameter and number of liver metastases may affect the immune response in patients with liver metastasis.
View article: Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer
Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer Open
Overall survival (OS) among patients with limited-disease small-cell lung cancer (LD-SCLC) receiving chemoradiotherapy can be significantly influenced by subsequent treatments. Thus, the present study aimed to examine the interplay between…
View article: A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab
A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab Open
Background The combination of nivolumab and ipilimumab, which act on different immune checkpoint molecules, is a promising first‐line treatment strategy for advanced nonsmall cell lung cancer (NSCLC). However, real‐world clinical data on t…
View article: Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer
Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer Open
MTV determined based on 18F-FDG uptake was a negative prognostic factor after Nivo-Ipi treatment, particularly in patients with histological findings of AC or PD-L1 <1%.
View article: Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer Open
First-line Nivo-Ipi therapy is effective in elderly patients with NSCLC. Although there was an increased incidence of pneumonitis, the treatment was manageable and presented as a viable treatment option. Notably, the occurrence of treatmen…
View article: Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare Case
Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare Case Open
View article: Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer
Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer Open
Background Two-deoxy-2-[fluorine-18]-fluoro-d-glucose ( 18 F-FDG) positron emission tomography (PET) is useful for detecting malignant lesions; however, the clinical significance of cardiac 18 F-FDG uptake in patients with cancer remains u…
View article: A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature
A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature Open
Background The standard treatment for patients in good general condition with limited-disease small cell lung cancer (LD-SCLC) is concurrent platinum/etoposide chemotherapy and thoracic radiotherapy (TRT). However, the efficacy and safety …
View article: Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation
Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation Open
Background/Aim: Granulocyte colony-stimulating factor (G-CSF)-producing neoplasms are relatively rare; however, little is known on the clinical features of G-CSF-producing lung cancer harboring activating epidermal growth factor receptor (…
View article: Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer
Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer Open
Background: Two-deoxy-2-[fluorine-18]-fluoro-d-glucose (18F-FDG) positron emission tomography (PET) is useful for detecting malignant lesions; however, the clinical significance of cardiac 18F-FDG uptake in patients w…
View article: Data from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Data from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy Open
CD4+ T-cell immunity helps clonal proliferation, migration, and cancer cell killing activity of CD8+ T cells and is essential in antitumor immune responses. To identify CD4+ T-cell clusters responsible for …
View article: Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy
Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy Open
The aim of the present study was to explore the relationship between tumor metabolic glycolysis and inflammatory or nutritional status in patients with advanced non-small cell lung cancer (NSCLC) who received programmed death-1 (PD-1) bloc…
View article: Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib Open
Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. The prognostic usefulness of ctDNA after first-line epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are limited. Therefore, th…
View article: Clinicopathological impact of <scp>VEGFR2</scp> and <scp>VEGF‐C</scp> in patients with <scp><i>EGFR</i></scp>‐major mutant <scp>NSCLC</scp> receiving osimertinib
Clinicopathological impact of <span>VEGFR2</span> and <span>VEGF‐C</span> in patients with <span><i>EGFR</i></span>‐major mutant <span>NSCLC</span> receiving osimertinib Open
Background Vascular endothelial growth factor (VEGF) has been identified as one of the resistant mechanisms to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, the relationship between the efficacy of osime…
View article: Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC
Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC Open
Background Biomarkers for predicting the outcome of ipilimumab plus nivolumab (Nivo-Ipi) treatment in cancer patients have not been identified. Herein, we investigated the prognostic significance of inflammatory and nutritional markers in …
View article: CD4<sup>+</sup>T-cell immunity of SARS-CoV-2 patients determine pneumonia development
CD4<sup>+</sup>T-cell immunity of SARS-CoV-2 patients determine pneumonia development Open
Most humans infected with SARS-CoV-2 will recover without developing pneumonia. A few SARS-CoV-2 infected patients, however, develop pneumonia, and occasionally develop cytokine storms. In such cases, it is assumed that there is an inadequ…
View article: Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer Open
Background The relationship between antinuclear antibody (ANA) and the efficacy of programmed death-1 (PD-1) blockade remains controversial. Here, we investigated the prognostic significance of ANA titer in patients with non-small cell lun…
View article: Supplementary Figure Legends from CD4<sup>+</sup> T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Supplementary Figure Legends from CD4<sup>+</sup> T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy Open
Supplementary Figure Legends
View article: Data from CD4<sup>+</sup> T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Data from CD4<sup>+</sup> T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy Open
Accumulating evidence indicates that CD8+ T cells in the tumor microenvironment and systemic CD4+ T-cell immunity play an important role in mediating durable antitumor responses. We longitudinally examined T-cell immu…
View article: Supplementary Figures and Tables from CD4<sup>+</sup> T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Supplementary Figures and Tables from CD4<sup>+</sup> T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy Open
Supplementary Figures and Tables